By Jaime Llinares Taboada

 

GSK PLC said Friday that China has approved a two-dose schedule for its Cervarix vaccine for girls aged nine to 14.

The healthcare company said that the vaccine is against certain types of cancer-causing human papillomavirus. In 2020, there were 110,000 new cases of cervical cancer and 59,000 deaths due to the disease in China, it said.

The authorization of the two-dose regime by the Chinese regulator adds to approvals in around 100 countries. The three-dose schedule remains on the label for girls and women aged 15-45 years in China, GSK said.

 

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

 

(END) Dow Jones Newswires

May 27, 2022 02:25 ET (06:25 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Gsk Charts.